Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Polyrizon Ltd. - Ordinary Shares (PLRZ)
Company Research
Source: GlobeNewswire
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies. The evaluation was performed using a validated silicone nasal cast model (Koken® LM-005) combined with quantitative image analysis. Results demonstrated that Polyrizon’s formulation achieved significantly higher deposition in the nasal vestibule region compared to the commercial reference product. Key Findings: Polyrizon’s advanced nasal formulation achieved 94.6% (±4.0%) depo
Show less
Read more
Impact Snapshot
Event Time:
PLRZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRZ alerts
High impacting Polyrizon Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PLRZ
News
- Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy BlockerPR Newswire
- Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet OperatorGlobeNewswire
- Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen FormulationGlobeNewswire
- Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company [Yahoo! Finance]Yahoo! Finance
- Polyrizon Intends to Acquire 51% Stake in Global Private Aviation CompanyGlobeNewswire
PLRZ
Sec Filings
- 2/26/26 - Form 6-K
- 2/6/26 - Form 6-K
- 2/4/26 - Form 6-K
- PLRZ's page on the SEC website